Physician profile
Jason Sherer
NPI 1770946352
$2,743.66
in general payments reported to CMS, 2019-2025
24 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.00 · 2023: $742 · 2024: $1,537 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,668.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $744.49 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Amgen INC. | $333.27 | 2023-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $229.60 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $220.61 | 2023-2024 | Verquvo, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $194.77 | 2023-2024 | Farxiga, Lokelma |
| Esperion Therapeutics, INC. | $161.01 | 2023-2024 | Nexletol |
| Boston Scientific Corporation | $147.12 | 2023 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $136.90 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $79.11 | 2023-2024 | Inpefa |
| Astellas Pharma US INC | $75.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.24 | 2023-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $43.30 | 2023-2024 | Camzyos, Eliquis |
| Novo Nordisk INC | $42.12 | 2024-2025 | Saxenda, Wegovy |
| Scpharmaceuticals INC. | $40.92 | 2023-2024 | |
| Kestra Medical Technology Services, INC. | $37.96 | 2024 | Assure Wcd |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $32.95 | 2023 | Telepatch Cardiac Monitor |
| Genzyme Corporation | $27.12 | 2024 | |
| Daiichi Sankyo INC. | $26.15 | 2025 | Injectafer |
| Aimmune Therapeutics, INC. | $23.88 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.69 | 2025 | |
| Lilly USA, LLC | $20.88 | 2024 | Mounjaro |
| Eisai INC. | $19.42 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.91 | 2023 | Jardiance |
| Dynavax Technologies Corporation | $16.24 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Sherer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.